About this episode

The episode discusses several novel drugs approved in 2025, focusing on their efficacy, safety, and considerations for use.

Listen in as our editors discuss several novel drugs approved in 2025, including two new eye drops, a new topical for chronic hand eczema, and an oral nonhormonal option for patients with menopausal hot flashes. They’ll review efficacy, safety, and considerations for use with these new treatment options. Aceclidine 1.44% Drops (Vizz) for PresbyopiaAcoltremon 0.003% Drops (Tryptyr) for Dry EyeDelgocitinib (Anzupgo) 2% Cream for Chronic Hand EczemaElinzanetant (Lynkuet) for Hot FlashesUse code ...

Topics covered

• new medications
• drug therapy
• patient care
• menopausal treatment
• chronic hand eczema
• eye drops

Keywords

• novel drugs
• eye drops
• chronic hand eczema
• menopausal hot flashes
• drug approval

Mentioned in this episode

Products: Aceclidine 1.44% Drops (Vizz), Acoltremon 0.003% Drops (Tryptyr), Delgocitinib (Anzupgo) 2% Cream, Elinzanetant (Lynkuet)

More episodes of Medication Talk - Expert Insights on Drug Therapy & Patient Care

• GLP-1 Agonists: Clinical Conundrums · April 1, 2026 · 39 min
• Putting Antimicrobial Stewardship Into Practice · March 1, 2026 · 38 min
• BONUS: More Notable New Meds of 2025 · February 19, 2026 · 21 min
• BONUS: Smoking and Vaping Cessation Conversations · January 22, 2026 · 28 min
• Smoking and Vaping Cessation · January 1, 2026 · 37 min
• Considerations with Oral Oncology Meds · December 1, 2025 · 36 min

Explore listener stats, chart rankings, contacts and more on the Medication Talk - Expert Insights on Drug Therapy & Patient Care podcast page.